Hepatitis B Annual

REVIEW ARTICLE
Year
: 2006  |  Volume : 3  |  Issue : 1  |  Page : 35--53

Entecavir : A review


Chee-Kiat Tan 
 Department of Gastroenterology and Hepatology, Singapore General Hospital, Singapore

Correspondence Address:
Chee-Kiat Tan
Department of Gastroenterology and Hepatology, Singapore General Hospital, Outram Road 169608
Singapore

Entecavir is the newest and most potent nucleoside analog to be licensed worldwide for the treatment of chronic hepatitis B infection. It has been shown to be more effective than lamivudine and adefovir in direct head-to-head comparison trials. It is also useful in the treatment of lamivudine-refractory patients. Entecavir is safe with no significant difference in adverse effects compared to lamivudine and adefovir. Available data for up to 2 years of continuous therapy showed no development of viral resistance in nucleos(t)ide-naοve patients. Resistance to entecavir occurs only in patients previously exposed to lamivudine and occurs at a rate of 9% after 2 years of continuous therapy with entecavir.


How to cite this article:
Tan CK. Entecavir : A review.Hep B Annual 2006;3:35-53


How to cite this URL:
Tan CK. Entecavir : A review. Hep B Annual [serial online] 2006 [cited 2019 Jun 25 ];3:35-53
Available from: http://www.hepatitisbannual.org/article.asp?issn=0972-9747;year=2006;volume=3;issue=1;spage=35;epage=53;aulast=Tan;type=0